Lviv clinical bulletin 2022, 3(39)-4(40): 45-53

https://orcid.org/10.25040/lkv2022.03-04.045

The Role Of HTRA Serine Peptidase 1, Vascular Endothelial Growth Factor А, Tumor Necrosis Factor Gene Polymorphisms in the Treatment Of Wet Age-Related Macular Degeneration

Posted onAuthorAdminЗалишити коментар / Leave a comment

N. Malachkova, O. M. M. Al-Jarrah

National Pirogov Memorial Medical University, Vinnytsya

Introduction. Age-related macular degeneration (AMD) of the retina is still considered the leading cause of vision loss in the elderly. The multifactoriality of the disease impairs the clinical effectiveness of modern AMD treatment methods. however, the study of single-nucleotide polymorphisms, in particular, of the HtrA serine peptidase 1 (HTRA1), vascular endothelial growth factor A (VEGF A) and tumor necrosis factor (TNF) genesis a promising link on the way to improve and develope more effective treatment strategies of the disease.

The Aim of the Study. To investigate role of HTRA 1, VEGF A and TNF gene polymorphisms in the treatment of wet age-related macular degeneration.

Materials and Methods. 162 people with diagnosed wet AMD took part in the investigation. They received anti-VEGF A therapy in the form of injections of aflibercept monthly for half a year. Structural changes of the eyes were studied using optical coherence tomography (OCT); polymerase chain reaction (PCR) studies were performed using a Bio-Rad CFX 96 apparatus (BioRad, USA) using a reagent package (Lytech, Russia). Statistical analysis of the obtained results was performed using a set of software packages Statistica 10 (StatSoft, Inc., USA) and SPSS 23.0.

Results. It was revealed best prognostic significance in patients with the TC rs2010963 genotype of the VEGFA gene was registered during the analysis of OCT 2 (RR=2.7; 95% CI 1.556 – 4.8), OCT 4 (RR=2.9 ; 95% CI 1.7 – 5.03) and OCT 8 (RR=2.6; 95% CI 1.6 – 4.12) sections, while in patients with the CC genotype these indicators in the OCT 2 section were: RR= 6.1; 95% CI 3.66 – 10.27; in OCT zone 4 RR=4.9; 95% CI 2.9 – 8.29, and in the OCT section 8: RR=4.23; 95% CI 2.7 – 6.556, which indicates a more pronounced influence of the CC genotype. When analyzing rs1800629 of the TNF gene, the best prognostic significance of the GA genotype was established in the OCT 4 (RR=1.77; 95% CI 1.218 – 2.56) and OCT 8 (RR=1.9; 95% CI 1.17 – 3.175) areas (p<0.05), with the AA genotype in OCT 4 (RR=3.77; 95% CI 2.17 – 6.58), OCT 8 (RR=3.1; 95% CI 1 .7 – 5.59) zones and when evaluating changes in visual acuity of patients with wet AMD (RR=4.2; 95% CI 2 – 8.98). No statistically significant results were found in the evaluation of the HTRA1 gene rs11200638 (p>0.05).

Conclusions. The data obtained in our study indicate a direct influence of the vascular endothelial growth factor A (rs2010963) and tumor necrosis factor (rs1800629) polymorphisms on the emergence of resistance to aflibercept. However, the study of this influence in the presence of the HtrA serine peptidase 1 gene rs11200638 requires further research.

References

  1. Ahmed R, Sharif D, Jaf M, Amin DM. Effect of TNF-α -308G/A (rs1800629) promoter POLYMORPHISM on the serum level of TNF-α among iraqi patients with generalized Vitiligo. Clin Cosmet Investig Dermatol. 2020;13:825-835.
  2. American Association for the Advancement of Science. The Runners-Up. Science. 2006;314:1850-1855.
  3. Baumal CR. Wet age-related macular degeneration: treatment advances to reduce the injection burden. Am J Manag Care. 2020;26(5 Suppl):S103-S111.
  4. Binder S. Loss of reactivity intravitreal anti-VEGF therapy: tachyphylaxis and tolerance? Br J Ophthalmol. 2012;96(1):1-2.
  5. Blasiak J, Watala C, Tuuminen R, Kivinen N, Koskela A, Uusitalo-Järvinen H et al. Expression Of VEGFA-regulating miRNAs and mortality wet J Cell Mol Med. 2019;23(12):8464-8471.
  6. Bonyadi MHJ, Bonyadi M, Ahmadieh H, Fotuhi N, Shoeibi N, Saadat S et al. Tumor necrosis factor gene polymorphisms in advanced non-exudative age-related macular degeneration. J Ophthalmic Vis Res. 2015;10(2):155-159.
  7. Busbee BG, Ho AC, Brown DM, Heier JS, Suñer IJ, Li Z et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013;120(5):1046-1056.
  8. Chernykh V, Shevchenko A, Konenkov V, Prokofiev V, Eremina A, Trunov A. TNF-α gene polymorphisms: association with age-related macular degeneration in Russian population. Int J Ophthalmol. 2019;12(1):25-29.
  9. Cruz-Gonzalez F, Cabrillo-Estevez L, Rivero-Gutierrez V, Sanchez-Jara A, DeJuan-Marcos L, Gonzalez-Sarmiento R. Influence of CFH, HTRA1 and ARMS2 polymorphisms in the response to intravitreal ranibizumab treatment for wet age-related macular degeneration in a Spanish population. Int J Ophthalmol. 2016;9(9):1304-1309.
  10. Deng Y, Qiao L, Du M, Qu C, Wan L, Li J et al. Age-related macular degeneration: Epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy. Genes Dis. 2022;9(1):62-79.
  11. Díaz-Villamarín X, Blánquez-Martínez D, Pozo-Agundo A, Pérez-Gutiérrez AM, Muñoz-Ávila JI, Antúnez-Rodríguez A et al. Genetic variants affecting anti-vegf drug response in polypoidal choroidal vasculopathy patients: a systematic review and meta-analysis. Genes (Basel). 2020;11(1335):1-13.
  12. El-Tahan RR, Ghoneim AM, El-Mashad N. TNF-α gene polymorphisms and expression. Springer Plus. 2016;5(1508):1-7.
  13. Falvo JV, Tsytsykova AV, Goldfeld AE. Transcriptional control of the TNF gene. Curr Dir Autoimmun. 2010;11:27-60.
  14. Farnoodian M, Wang S, Dietz J, Nickells RW, Sorenson CM, Sheibani N. Negative regulators of angiogenesis: Important targets for treatment of exudative AMD. ClinSci (Lond). 2017;131(15):1763-1780.
  15. Fischer R, Maier O. Interrelation of oxidative stress and inflammation in neurodegenerative disease: role of TNF. Oxid Med Cell Longev. 2015;2015(610813):1-18.
  16. GeneCards – the human gene database. TNF gene – geneCards; 2005. Available from: https://www.genecards.org/cgi-bin/carddisp.pl?gene=TNF.
  17. GeneCards – the human gene database. VEGFA gene – geneCards; 2005. Available from: https://www.genecards.org/cgi-bin/carddisp.pl?gene=VEGFA.
  18. Habibi I, Kort F, Sfar I, Chebil A, Bouraoui R, Abdallah TB et al. Effect of Risk Alleles in CFH, C3, and VEGFA on the Response to Intravitreal Bevacizumab in Tunisian Patients with Neovascular Age-related Macular Degeneration. Klin Monbl Augenheilkd. 2016;233(4):465-470.
  19. Hachana S, Fontaine O, Sapieha P, Lesk M, Couture R, Vaucher E. The effects of anti-VEGF and kinin B1 receptor blockade on retinal inflammation in laser-induced choroidal neovascularization. Br J Pharmacol. 2020;177(9):1949-1966.
  20. Huang C, Xu Y, Li X, Wang W. Vascular endothelial growth factor A polymorphisms and age-related macular degeneration: a systematic review and meta-analysis. Mol Vis. 2013;19:1211-1221.
  21. Imai D, Mori K, Horie-Inoue K, Gehlbach PL, Awata T, Inoue S et al. CFH, VEGF, and PEDF genotypes and the response to intravitreous injection of bevacizumab for the treatment of age-related macular degeneration. J Ocul Biol Dis Infor. 2010;3(2):53-59.
  22. Janik-Papis K, Zaras M, Krzyzanowska A, Wozniak K, Blasiak J, Szaflik J et al. Association between vascular endothelial growth factor gene polymorphisms and age-related macular degeneration in a Polish population. Exp Mol Pathol. 2009;87(3):234-238.
  23. Jiang Q, Li Z, Tao T, Duan R, Wang X, Su W. TNF-α in uveitis: from bench to clinic. Front Pharmacol. 2021;12(740057):1-13.
  24. Kang HK, Yoon MH, Lee DH, Chin HS. Pharmacogenetic influence of LOC387715/HTRA1 on the efficacy of bevacizumab treatment for age-related macular degeneration in a Korean population. Korean J Ophthalmol. 2012;26(6):414-422.
  25. Khaloo P, Qahremani R, Rabizadeh S, Omidi M, Rajab A, Heidari F et al. Nitric oxide and TNF-α are correlates of diabetic retinopathy independent of hs-CRP and HbA1c. Endocrine. 2020;69:536-541.
  26. Lin F, Wang P, Chuang Y, Wang J, Wong VHY, Bui BV et al. Gene therapy intervention in neovascular eye disease: a recent update. Mol Ther. 2020;28(10):2120-2138.
  27. Liu B, Wei J, Li M, Jiang J, Zhang H, Yang L et al. Association of common genetic variants in VEGFA with biliary atresia susceptibility in North western Han Chinese. Gene. 2017;628:87-92.
  28. Lotery A, Trump D. Progress in defining the molecular biology of age related macular degeneration. Hum Genet. 2007;122(3-4):219-236.
  29. Mohamad NA, Ramachandran V, Isa HM, Chan YM, Ngah NF, Ching SM et al. Association of HTRA1 and ARMS2 gene polymorphisms with response to intravitreal ranibizumab among neovascular age-related macular degenerative subjects. Hum Genomics. 2019;13(13):1-12.
  30. Nakanishi H, Gotoh N, Yamada R, Yamashiro K, Otani A, Hayashi H et al. ARMS2/HTRA1 and CFH polymorphisms are not associated with choroidal neovascularization in highly myopic eyes of the elderly Japanese population. Eye. 2010;24:1078-1084.
  31. Nashine S. Potential therapeutic candidates for age-related macular degeneration (AMD). Cells. 2021;10(2483):1-16.
  32. Passan S, Goyal S, Bhat MA, Singh D, Vanita V. Association of TNF-α gene alterations (c.-238G>A, c.-308G>A, c.-857C>T, c.-863C>A) with primary glaucoma in north Indian cohort. Gene. 2019;709:25-35.
  33. Pinci F, Gaidt MM, Jung C, Kuut G, Jackson MA, Bauernfried S, Hornung V. C-tag TNF: A reporter system to study TNF shedding. J Biol Chem. 2020;295(52):18065-18075.
  34. Ricci F, Bandello F, Navarra P, Staurenghi G, Stumpp M, Zarbin M. Neovascular age-related macular degeneration: therapeutic management and new-upcoming approaches. Int J Mol Sci. 2020;21(8242):1-40.
  35. Rinsky B, Hagbi-Levi S, Elbaz-Hayoun S, Grunin M, Chowers I. Characterizing the effect of supplements on the phenotype of cultured macrophages from patients with age-related macular degeneration. Mol Vis. 2017;23:889-899.
  36. Stahl A. The diagnosis and treatment of age-related macular degeneration. Dtsch Arztebl Int. 2020;117(29-30):513-520.
  37. Stefano JE, Bird J, Kyazike J, Cheng AW, Boudanova E, Dwyer M et al. High-affinity VEGF antagonists by oligomerization of a minimal sequence VEGF-binding domain. Bioconjug Chem. 2012;23(12):2354-2364.
  38. Stepp MA, Menko AS. Immune responses to injury and their links to eye disease. Transl Res. 2021;236:52-71.
  39. Wan L, Lin H, Tsai Y, Lee C, Tsai C, Tsai F et al. Tumor necrosis factor-α gene polymorphisms in age-related macular degeneration. Retina. 2010;30(10):1595-1600.
  40. Wei X, Chen Y, Wu L, Cui L, Hu D, Zeng X. Tumor necrosis factor-α G-308A (rs1800629) polymorphism and aggressive periodontitis susceptibility: a meta-analysis of 16 case-control studies. Sci Rep. 2016;6(19099):1-8.
  41. Woo HJ, Yu C, Kumar K, Gold B, Reifman J. Genotype distribution-based inference of collective effects in genome-wide association studies: in sights to age-related macular degeneration disease mechanism. BMC Genomics. 2016;17(695):1-20.
  42. World Medical Association. Ethical principles for medical research involving human subjects. 2018; WMA declaration of Helsinki. Available from: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/
  43. Yang S, Zhao J, Sun X. Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review. Drug Des Devel Ther. 2016;10:1857-1867.
  44. Zacks DN, Kocab AJ, Choi JJ, Gregory-Ksander MS, Cano M, Hand JT. Cell death in AMD: the rationale for targeting fas. J Clin Med. 2022;11(592):1-14.
  45. Zhang Y, Cao Y, Xin L, Gao N, Liu B, Li Y. Association between rs1800629 polymorphism in tumor necrosis factor-α gene and dilated cardiomyopathy susceptibility. Medicine. 2018;97(50):e13386.
  46. Zhou Y, Chen C, Wang Y, Tong Y, Fang X, Li L et al. Association between polymorphism rs11200638 in the HTRA1 gene and the response to anti-VEGF treatment of exudative AMD: a meta-analysis. BMC Ophthalmology. 2017;17(97):1-9.